Arecor to Acquire Tetris Pharma for Ogluo
Shots:
- Arecor to acquire Tetris Pharma to commercialize Ogluo in the UK and EEA
- In July 2021, Xeris & Tetris Pharma collaborated to commercialize Ogluo in the EEA, the UK, and Switzerland where Xeris received $71M in its first commercial sale and is eligible to receive sales-related milestones along with royalty. Xeris was responsible for product supply in the territory
- Ogluo is the first ready-to-use, pre-mixed, pre-measured glucagon injection for the treatment of sev. hypoglycaemia in pediatric and adult patients ages ≥2yrs. with diabetes & has received the marketing authorization from the EC on Feb 11, 2021
Ref: Businesswire | Image: Tetris Pharma
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
